Hoth Therapeutics Inc SEC Filings

Hoth Therapeutics amended its prospectus supplement to expand its at-the-market program with H.C. Wainwright. The company is now offering up to $4,821,200 of common stock under the existing ATM agreement, after effectiveness and pursuant to General Instruction I.B.6 of Form S-3.

Since launching the ATM, Hoth has sold 3,919,559 shares for gross proceeds of about $5.5 million. The company cites a public float of approximately $30,968,682, which caps primary offerings at one-third of float over any 12-month period; the new $4,821,200 capacity reflects that limit. Shares trade on Nasdaq as “HOTH,” with a last reported sale price of $1.28 on November 12, 2025.

Hoth Therapeutics (HOTH) filed its Q3 2025 10‑Q, reporting no revenue and a net loss of $4.11 million for the quarter as operating expenses reached $4.08 million. For the nine months, the company recorded a net loss of $9.78 million.

Liquidity remained stable with cash and cash equivalents of $7.85 million as of September 30, 2025. Year‑to‑date, the company used $7.65 million in operating cash and received $8.76 million from financing, including warrant exercises and equity sales. Management states current cash is sufficient to fund operations for at least 12 months from the issuance date of these financial statements, while noting additional capital will be needed to advance programs.

The company maintained an ATM program with total capacity of $7.7 million; approximately $5.5 million of common stock had been sold under the program as of November 11, 2025. Shares outstanding were 15,514,312 as of November 11, 2025. Hoth also reported crypto assets at fair value of $274,695 (BTC, ETH, SOL). Equity activity included the CEO’s 800,000-share restricted stock grant in August.

Hoth Therapeutics (HOTH) filed a Form 8-K to announce that management has prepared investor presentation materials for use on and after October 17, 2025. The materials are included as Exhibit 99.1 and provide summary information about the company’s operations and performance.

The presentation speaks as of the 8-K date, and the company notes it may update the materials but disclaims any obligation to do so. No transactions, financial results, or new guidance are disclosed in this filing.

Robb Knie, CEO and President and a director of Hoth Therapeutics, acquired 800,000 shares of restricted common stock under the company’s Amended and Restated 2022 Equity Incentive Plan; the award vested in full at grant and was issued at $0 per share, bringing his post-award beneficial ownership to 858,131 shares. The next day he sold 310,744 shares at $1.21 per share, reducing his beneficial ownership to 547,387 shares. The Form 4 shows the acquisition was labeled as an issuance that vested on grant and the sale was reported separately. The filing was signed by an attorney-in-fact on behalf of Mr. Knie.

Hoth Therapeutics, Inc. disclosed a material agreement: an Employment Agreement between the company and Robb Knie dated August 22, 2025. The filing is an Form 8-K reporting that the employment contract was furnished as an exhibit and the document is signed by Robb Knie in his capacity as Chief Executive Officer. No financial terms, termination provisions, equity awards, or other compensation details appear in the provided text, and there are no financial statements or earnings information included.

Hoth Therapeutics, Inc. reported $9.0 million in cash and cash equivalents at June 30, 2025, up from $7.0 million at year-end 2024, and total assets of $10.1 million. The company recorded a six-month net loss of $5.68 million versus $3.86 million in the prior-year period, driven in part by a $1.25 million immediate expensing of acquired patent applications and higher research and development spending. Weighted average shares increased materially, lowering six-month loss per share to $0.44 from $0.68 a year earlier despite a larger absolute loss.

Operating cash used was $5.16 million for the six months, while financing activities provided $7.13 million, including $5.625 million from warrant exercises. Management states current cash is sufficient to fund operations for at least 12 months from issuance, but additional capital will be required for longer-term development and regulatory plans. The company continues clinical and preclinical programs across multiple candidates and maintains an ATM facility with selling capacity expanded to $7.7 million.

Hoth Therapeutics has filed an 8-K report announcing the preparation of new presentation materials that management plans to use for company presentations starting June 24, 2025. The materials are included as Exhibit 99.1 to the Current Report.

Key points from the filing:

• The presentation materials contain summary information that should be considered alongside the company's SEC filings and other public announcements
• The company maintains discretion to update the materials but has no obligation to do so
• Information provided under Item 7.01 and Exhibit 99.1 is furnished rather than "filed" under SEC regulations
• The information will not be incorporated by reference into any Securities Act or Exchange Act filings

The filing was signed by CEO Robb Knie and includes the standard Cover Page Interactive Data File in Inline XBRL format.

Hoth Therapeutics, Inc. ("HOTH") reported that, on June 18, 2025, The Nasdaq Stock Market notified the company that its common stock satisfied the minimum bid price requirement of $1.00 per share for at least ten consecutive business days, thereby restoring full compliance with Nasdaq Listing Rule 5550(a)(2). The company disclosed the notification in this Form 8-K and simultaneously issued a press release, furnished as Exhibit 99.1.